Invus Opportunities
VC Fund
Invus Opportunities is a sister fund to The Invus Group, an equity investment firm founded in 1985 with over $8 billion of evergreen capital. Invus Opportunities is focused on partnering with market-leading management teams and investors in private transactions globally. With a differentiated heritage and capital base, Invus Opportunities brings acomplementary dimension to growing companies and investor groups seeking to create lasting value. Invus Opportunities both leads rounds of financing and co-invests in syndicated financings, and currently manages over $1.5 billion.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries Invus Opportunities invests in
Stages Invus Opportunities invests in
Countries Invus Opportunities invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bryan Kim
|
|||
|
Sacha Lainovic
|
|||
Investment Focus
Industry
- Financial Services 5 (11%)
- E-Commerce 3 (7%)
- Therapeutics 3 (7%)
- Information Technology 3 (7%)
- Credit 2 (4%)
Stage
- Series A 3 (7%)
- Series B 3 (7%)
- Post-IPO Equity 3 (7%)
- Series C 2 (4%)
- Series E 2 (4%)
Country
- United States 9 (20%)
- India 1 (2%)
- Brazil 1 (2%)
- France 1 (2%)
- Mexico 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bryan Kim
Partner at Invus Opportunities
|
Partner at Invus Opportunities | Total investments: 3 | Find email | |
Benjamin Tsai
Partner
|
Partner | Total investments: 6 | Find email | |
|
Sacha Lainovic
Managing Director & Founder
|
Managing Director & Founder | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Osanni Bio
|
Osanni Bio is a biotechnology company developing therapies aimed at preventing and reversing blindness caused by retinal diseases. Leveraging design-thinking in drug development, Osanni focuses on novel ocular disease treatments intended to restore vision rather than just slow disease progression | $190M / Series B / Jun 23, 2026 | |
MedinCell
|
MedinCell is an injectable slow-release drug specialist company. | $44.7M / Post-IPO Equity / Feb 19, 2025 | |
Rain
|
Rain is the trusted leader in employee-centric financial wellness solutions, serving middle-market and enterprise organizations nationwide. Through a comprehensive suite of offerings, including earned wage access and other financial wellness benefits, Rain seamlessly integrates with any organization's existing infrastructure, providing theflexibility essential for effective financial management. Rain’s mission is to empower employees to reach financial freedom. At Rain, financial freedom means being able to afford everyday life without stressing about pay dates or pay cycles. | $75M / Series B / Feb 10, 2025 | |
Zenflow
|
Zenflow was founded in 2014 by a team of Stanford University Biodesign Fellows working in collaboration with top global urologists. After witnessing patients' frustration with existing treatment options, the founders made it their mission to find a better solution to this large unmet clinical need. | $24M / Series C / Nov 18, 2024 | |
Vinted
|
Vinted operates an online marketplace intended to make second-hand the first choice. Its platform offers a peer-to-peer marketplace for girls and women to buy, sell, and swap clothes with an online chatting feature, enabling users to shop with ease at low cost. It was founded in 2008 and headquartered in Apskritis, Lithuania. | $368M / Secondary Market / Oct 24, 2024 | |
Mirador Therapeutics
|
Mirador Therapeutics develops precision medicines for immune-mediated inflammatory and fibrotic diseases using an integrated discovery and development platform. The company’s Mirador360 engine combines human genetics, multi-modal data, and analytical tools to identify therapeutic targets, support patient stratification, and inform drug design. Itsofferings include research programs and pipeline assets aimed at conditions such as chronic inflammation and tissue fibrosis. Mirador Therapeutics works with scientific and medical stakeholders to advance targeted therapeutic candidates through preclinical and clinical development. | $400M / Series A / Mar 21, 2024 | |
Mission Lane
|
At Mission Lane, it's our goal to provide access to responsible credit on transparent terms and to create paths to better financial health. Building world-class credit cards is how we're getting there.Mission Lane is a new company dedicated to helping everyone have access to fair and clear credit. We believe in creating a relationshipwhere everybody wins. Our customers do well when they succeed with our credit cards. We do well when they prosper. It's that simple. We’re here to provide the best-in-class service our customers deserve. Join us, because where we’re going, we’re going together. | Venture - Series Unknown / Feb 16, 2024 | |
Adevinta
|
Adevinta is a marketplace specialist. They help their local digital marketplaces thrive through global connections and networks of knowledge. Their marketplaces unlock the full value in every person, place and thing – helping local communities prosper and leaving a positive footprint on the world. | Post-IPO Equity / Jan 01, 2024 | |
Mynd
|
Mynd is a customer-first, tech-enabled property management firm focused on the rental sector. The company focuses on managing single-family rental properties and offers a range of solutions to help clients efficiently handle their real estate investments.Mynd's services typically include property marketing, tenant screening, rent collection,property maintenance, and accounting. They aim to streamline the property management process, alleviate the burdens of day-to-day management for property owners, and maximize the potential returns on their investments. The company uses technology and data analytics to enhance property performance, guarantee timely client communication, and offer insightful information that helps property owners make wise decisions. Landlords can receive financial reports, real-time information about their properties, and contact Mynd's property management team via their digital platforms and tools. | $30M / Jul 20, 2023 | |
Presidio Medical
|
Presidio Medical is a medtech company that develops a transformational neuromodulation platform. It enables people to receive remedies for disorders affecting neuronal activity. | $72M / Series C / Jun 26, 2023 | |
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Invus Opportunities invest in?
Invus Opportunities invests primarily in Financial Services, E-Commerce and Therapeutics startups, most often at Series A and Series B stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Invus Opportunities?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Invus Opportunities?
The team at Invus Opportunities includes Bryan Kim (Partner at Invus Opportunities), Benjamin Tsai (Partner) and Sacha Lainovic (Managing Director & Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
